Oxford Immunotec Global PLC Announces Pricing of Initial Public Offering Oxford, UK and Marlborough, MA, November 22, 2013 – Oxford Immunotec Global PLC (NASDAQ: OXFD) (the “Company”) announced today that its initial public offering of 5,360,000 ordinary...
Durata Therapeutics Announces FDA’s Acceptance for Priority Review of NDA for Dalvance™ (dalbavancin hydrochloride) CHICAGO, Nov. 26, 2013 (GLOBE NEWSWIRE) — Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that the New Drug Application (NDA) for...
Kit Check Announces a Pharmacy Kit Accelerator Program with No Cost for Software and Hardware Washington, DC – December 3, 2013 – Kit Check™ today announced the Pharmacy Kit Accelerator Program that provides pharmacy kit automation software and hardware free of...
Kit Check launches Anesthesia Check to automate Operating Room Syringe Labeling and Medication Tracking Orlando, FL – December 9, 2013 – Kit Check™, the leader in hospital pharmacy kit automation, today announced the launch of Anesthesia Check™, a new...
US FDA Grants Orphan Drug Designation to Versartis’ Treatment for Growth Hormone Deficiency Redwood City, CA – December 18, 2013 – Versartis, Inc., an endocrine-focused biopharmaceutical company, has received US Food and Drug Administration (FDA) orphan drug...
Recent Comments